Form 4: Zoetis Director Reed Acquires 1,936 Restricted Stock Units

Zoetis Inc. Director Willie M. Reed reported the acquisition and vesting of 1,936 restricted stock units on February 18, 2026, and disclosed beneficial ownership of 1,619.3325 RSUs that vested on February 19, 2025.

Summary

• Willie M. Reed, a Director at Zoetis Inc. (ZTS), reported the acquisition of 1,936 Restricted Stock Units (RSUs) on February 18, 2026.
• These 1,936 RSUs vested and were settled in shares of Zoetis Inc. common stock on February 18, 2026, contingent on Mr. Reed's continued service.
• Mr. Reed also reported beneficial ownership of 1,619.3325 Restricted Stock Units from a prior grant, which vested and settled in shares of Zoetis Inc. common stock on February 19, 2025.
• Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock.
• The RSUs were granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, including dividend equivalent units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and alignment of director interests with shareholders, without indicating any significant operational or financial changes.

Positives

• Director Willie M. Reed's acquisition of 1,936 Restricted Stock Units aligns his interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The grant is part of an established equity incentive plan (Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan), indicating a structured approach to executive compensation.

Future Outlook

The reported transactions reflect the ongoing equity compensation structure for Director Reed, with the recent vesting of RSUs contributing to his direct beneficial ownership of Zoetis common stock.

Industry Context

StockSavvy.ai notes that the grant and vesting of Restricted Stock Units to directors is a standard practice in the pharmaceutical and animal health industries, aligning executive incentives with long-term shareholder value. This type of compensation is common across publicly traded companies to retain talent and encourage performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely adopted practice among S&P 500 companies, including peers in the animal health sector like Elanco Animal Health (ELAN) and IDEXX Laboratories (IDXX).
• The vesting schedule, with units vesting on specific anniversaries, is consistent with industry norms designed to promote long-term commitment and performance.
• The specific number of units granted would need to be benchmarked against the total compensation packages of directors at comparable market capitalization companies within the sector to assess its relative size, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's financial interests with shareholder value, as the units' value is tied to the company's stock performance.

Key Dates

Keywords

Zoetis, ZTS, Willie M. Reed, Director, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Form 4, Corporate Governance, Executive Compensation